As of 2025-07-23, the Intrinsic Value of CanSino Biologics Inc (688185.SS) is 194.58 CNY. This 688185.SS valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 66.84 CNY, the upside of CanSino Biologics Inc is 191.10%.
The range of the Intrinsic Value is 114.98 - 271.17 CNY
Based on its market price of 66.84 CNY and our intrinsic valuation, CanSino Biologics Inc (688185.SS) is undervalued by 191.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (830.59) - (300.82) | (432.02) | -746.4% |
| DCF (Growth 10y) | (304.14) - (767.69) | (420.03) | -728.4% |
| DCF (EBITDA 5y) | 114.98 - 271.17 | 194.58 | 191.1% |
| DCF (EBITDA 10y) | 153.94 - 436.77 | 290.87 | 335.2% |
| Fair Value | -36.49 - -36.49 | -36.49 | -154.59% |
| P/E | (35.76) - (36.92) | (35.50) | -153.1% |
| EV/EBITDA | (27.13) - 70.80 | 16.03 | -76.0% |
| EPV | (141.88) - (185.01) | (163.44) | -344.5% |
| DDM - Stable | (14.39) - (53.26) | (33.83) | -150.6% |
| DDM - Multi | (39.96) - (116.98) | (59.82) | -189.5% |
| Market Cap (mil) | 10,090.83 |
| Beta | 1.29 |
| Outstanding shares (mil) | 150.97 |
| Enterprise Value (mil) | 10,544.43 |
| Market risk premium | 6.13% |
| Cost of Equity | 8.78% |
| Cost of Debt | 5.00% |
| WACC | 8.14% |